Cancer evolves through a multistep process that occurs by the temporal accumulation of genetic mutations mediated by intracellular and extracellular cues. We observe that exosomes isolated from pancreatic cancer cells, but not normal pancreatic cells, can initiate the first step of malignant cell transformation. Injection of exosome-initiated transformed cells into mice results in aggressive 5 tumor growth. Using proteomic profiling and DNA sequencing of exosome-treated and transformed cells, we show that cancer cell exosomes act as a classic initiator by causing random genetic changes in recipient cells. Our studies provide new insight into a function of cancer cell exosomes and how they might specifically contribute to orchestrated local cell transformation.
Abstract:
Cancer evolves through a multistep process that occurs by the temporal accumulation of genetic mutations mediated by intracellular and extracellular cues. We observe that exosomes isolated from pancreatic cancer cells, but not normal pancreatic cells, can initiate the first step of malignant cell transformation. Injection of exosome-initiated transformed cells into mice results in aggressive 5 tumor growth. Using proteomic profiling and DNA sequencing of exosome-treated and transformed cells, we show that cancer cell exosomes act as a classic initiator by causing random genetic changes in recipient cells. Our studies provide new insight into a function of cancer cell exosomes and how they might specifically contribute to orchestrated local cell transformation.
Main Text: 10 Within the tumor microenvironment, a dynamic molecular communication between tumor and surrounding stromal cells is a well-recognized feature of cancer progression (1, 2). The conversation at the primary tumor site, as well as at distant locations, is mediated through many secreted factors including exosomes; small (30-150nm) secreted extracellular vesicles (sEV) shed by normal and malignant cells (3) (4) (5) (6) . Interest in exosomes and their mechanism(s) of biogenesis 15 and function has emerged as a promising, yet controversial, field of research. Based on multi-omic studies, these sEV are known to carry heterogeneous cargo composed of proteins, metabolites, genetic material (DNA and microRNAs), and lipids (7) (8) (9) (10) (11) (12) . They are selectively packaged and transferred into recipient cells acting as vehicles in intercellular communication in normal physiological and pathological conditions (13) . A growing body of evidence shows sEV are crucial 20 in shaping the local tumor microenvironment to promote cancer progression by advancing tumor metastasis (4, 14) . Although there is a major emphasis on describing the function of exosomes in metastasis and interactions between local tumor microenvironments, less effort has been invested 3 in analyzing their possible contribution to transforming a normal cell into a malignant cell. Since pancreatic cancer is a lethal metastatic disease that lacks efficient curative treatment, we raised the question of whether sEV, secreted by pancreatic cancer cells, participate directly in the process of cellular transformation (15) .
Malignant transformation of a normal cell occurs in a stepwise fashion. Initial changes 5 induced by environmental exposure, even with relatively low doses or genetic cues, can result in the reprogramming of a normal cell to a less differentiated state that is receptive to additional genetic alterations resulting in uncontrolled growth and ultimately cancer. The classic 2-stage in vitro cell transformation assay is a tiered system for transformation that was created for screening potential carcinogenic factors (16) (17) (18) ). In this system, cells are first treated with a suspected 10 carcinogen, called an initiator, which causes random genetic changes in a pool of normal cells.
Subsequently, these initiated cells are exposed to a promoter, which induces further genetic alterations resulting in cell transformation and observed as foci on a cell culture plate ( Fig. 1A ) (18, 19) . This 2-stage assay provides sensitivity in detecting a wider range of initiating agents that may not show obvious transforming activity without a promoter (18). With the recent indications 15 that exosomes are emerging contributors to normal physiology and tumor promotion, we asked a simple question: can exosomes function as an initiator or promoter during the transformation of a normal cell to a cancer cell?
To address this question, we utilized the classic cell transformation assay with NIH/3T3 cells using 3-methylcholanthrene (MCA) and tetradecanoyl phorbol acetate (TPA) as controls for 20 an initiator and promoter, respectively ( Fig. 1A) (18, 20) . Untreated cells or cells treated with MCA or TPA alone showed low levels of background foci, as defined by criteria on focus scoring ( Fig. 1B and C, table S2 ) (19) . By contrast, cells treated for three days with MCA (initiator) 4 followed by two weeks of TPA treatment (promoter) resulted in the consistent formation of 3-4 foci per well ( Fig. 1B and C, table S2 ). Therefore, only after treatment with both an initiator and promoter do we observe an increased number of foci above background levels ( Fig. 1B and C) .
To investigate whether exosomes can act as an initiator or promoter, we isolated exosomes from a pancreatic cancer cell line, Capan-2, using an established ultrafiltration protocol (21) . Prior 5 to treating cells with exosomes, we validated the purification by following a published minimal criteria protocol, with follow-up assays including electron microscopy, mass spectrometry, and immunoblot analysis on biological triplicates, to confirm rigor and reproducibility of our exosome preparations (fig. S1A to G, table S1) (22, 23) . Treatment of cells with only Capan-2 exosomes for the duration of the initiation and promotion steps (three weeks) showed a low level of 10 background transformation activity (Fig. 1C, table S2) . Similarly, when testing Capan-2 exosomes as a promoter, with the initiator MCA, we also observed background transformation activity comparable to control treatments (Fig. 1C, table S2 ). However, when Capan-2 exosomes were used as the initiator, with the promoter TPA, we observed comparable foci formation (3-4 foci per well) to the traditional MCA/TPA treatment (Fig. 1C, table S2 ). Therefore, Capan-2 exosomes 15 can function as an initiator, when combined with the promoter TPA, to induce cellular transformation.
We repeated these experiments with exosomes isolated from other pancreatic cancer cells, including Mia PACA-2, Panc-1, and BxPC-3, and exosomes isolated from normal immortalized pancreatic cells (HPDE) (Fig. 1C, fig. S2A, table S3 ). We observed that, similar to Capan-2 20 exosomes, Mia PACA-2 and Panc-1 cancer cell exosomes can function as an initiator, but not alone or as a promoter, to induce cellular transformation (Fig. 1C, fig. S2A ). These three pancreatic cell lines (Capan-2, Mia PACA-2, and Panc-1) contain oncogenic mutations in the Ras gene, whereas, the BxPC-3 cell line contains a wild type Ras gene. Considering exosomes with oncogenic KRAS can act as an initiator, we tested whether BxPC-3 has the same initiator activity ( fig. S2A ). We conclude that the observed exosome-mediated initiator activity is independent of the state of the Ras gene, as all four pancreatic cancer cell lines, including BxPC-3, have the ability to function as an initiator ( fig. S2A) . Importantly, exosomes isolated from the normal 5 immortalized pancreatic cell line HPDE were unable to induce cellular transformation when used as an initiator in the assay (Fig. 1C) . Therefore, pancreatic cancer cell exosomes, but not exosomes isolated from normal pancreatic cells, can initiate cellular transformation.
A common characteristic of initiators in the cellular transformation assay is that the initiator can function with multiple promoters to induce cell transformation (24, 25) . To test 10 whether the pancreatic cancer cell exosomes could act as an initiator with other promoters, we replaced TPA with another common promoter, cadmium chloride (CdCl 2 ), in the transformation assay (24, 26, 27) . We observed that cells treated with either MCA or Capan-2 exosomes as an initiator followed by treatment with CdCl 2 as a promoter resulted in transformation of cells, similar to what was observed when using TPA as the promoter ( fig. S2B, table S4 ). Treatment of cells 15 with CdCl 2 alone resulted in background levels of foci, reiterating the fact that cell transformation is dependent on both initiation and promotion. These results indicate that exosomes isolated from pancreatic cancer cells are indeed acting as general initiators in the transformation assay and are not dependent on a specific promoter.
An important step of assessing the tumorigenic property of transformed cells is their ability 20 to form tumors in vivo. To determine whether exosome-mediated transformed cells have the capacity to form tumors when injected subcutaneously into immunocompromised mice, we isolated and expanded foci cells from the MCA/TPA and Capan-2 exosome/TPA experiments. The 6 cells from these foci were then injected into NSG (NOD scid gamma) mice at three different concentrations and the mice were followed for the presence of measurable tumor formation ( Fig   1D, fig. S3A ). As a control, non-transformed NIH/3T3 cells were injected into mice at the highest concentration. Tumor growth was observed in mice injected with cells from MCA/TPA and Capan-2 exosome/TPA foci, but not with NIH/3T3 cells (Fig. 1D) . The appearance of tumors 5 correlated with the number of cells injected into mice such that higher concentration of cells resulted in faster growth and ultimately larger tumors (Fig. 1D, fig. S3A ). Histological analysis confirmed that the tumors are fibrosarcomas, as expected from transformed cells of mesenchymal origin ( fig. S3B) . To support the results obtained from in vitro experiments with other cancer cell exosomes, we performed the same in vivo studies in mice using Mia PACA-2 exosome/TPA, Panc-10 1 exosome/TPA, and BxPC-3 exosome/TPA foci. We observed that cells from these cancer cell exosome-initiated foci also formed tumors when injected into mice ( fig. S2C) . These studies clearly demonstrate that pancreatic cancer cell exosomes, independent of the state of the Ras gene, can function as an initiator to produce transformed cells that can induce tumor growth when injected into mice. 15 We note here that the exosomes used in our assays are derived from human cancer cell lines whereas the "normal" cells used in the cell transformation assay are NIH/3T3 cells from murine origin. Previous studies have shown highly conserved molecular functions across human and mouse, including the regulation of cell division, DNA replication, and DNA repair (28).
Moreover, since some of the microRNAs are conserved between human and mice (29) and show 20 a proclivity to change signaling in a treated cell, we first analyzed microRNA associated with cancer cell (Capan-2) and normal cell (HPDE) exosomes for differences. Analysis showed that a large majority of microRNA present were found to be upregulated in cancer cell exosomes 7 compared to normal cell exosomes ( fig. S4, table S5 ). Considering this, we analyzed whether the three-day initiator treatment with the human cancer cell exosomes could globally change signaling in the murine NIH/3T3 cells used in the cell transformation assay.
To asses this, NIH/3T3 cells were either left untreated or treated for three days with Capan-2 exosomes or MCA as the initiator followed by two days of recovery. Cells were harvested, and 5 total protein was analyzed by mass spectrometry. As expected, NIH/3T3 cells left untreated or treated with MCA showed no marked global changes in protein content ( Fig. 2A) . MCA functions by incorporating random mutations to initiate cellular transformation (30) and, therefore, it is expected that changes to proteins in any one cell among the total population would not be feasible to detect. Interestingly, we observed a similar proteomic profile of NIH/3T3 cells treated for three 10 days with Capan-2 exosomes, showing that initiation alone is not altering the protein composition of cells ( Fig. 2A) . In retrospect, these observations are not so surprising because it is known that exosomes do not uniformly contain the same pool of proteins, lipids, metabolites, or microRNAs, but rather each exosome contains a unique repertoire of biological molecules (8, 11, 12) . Therefore, as observed with other initiators such as MCA, cancer cell exosomes are likely causing random 15 molecular changes across the population of treated NIH/3T3 cells that cannot be detected amongst the overall protein composition of cells.
Based on these observations, we propose that cancer cell exosomes have the capacity to act as an initiator by incorporating random changes to mediate the first step in cellular transformation. We predict that detection of these single changes within the total population of 20 MCA-or cancer cell exosome-treated cells would be like trying to find a "needle in a haystack". Therefore, we turned to the foci that are formed during the 2-stage cellular transformation assay to analyze and compare proteomic and exome profiles of untreated NIH/3T3 cells, three 8 MCA/TPA foci, and three Capan-2 exosome/TPA foci. Analyses of the proteomic profiles of these samples revealed that the transformed cells had diverged significantly from the control NIH/3T3 cells (Fig. 2B) . Venn diagrams comparing the three MCA/TPA foci and the three Capan-2 exosome/TPA foci revealed unique differences in the protein composition of each of the transformed cell samples, indicating that the initiator and promoter events combined to result in 5 diverse changes to proteins in foci of transformed cells. Further, it appears that these changes are not uniform when comparing foci formed from the same treatment (Fig. 2B) .
Exome-seq analysis was performed in triplicates for MCA/TPA and Capan-2 exosome/TPA foci to better understand the genetic mechanism of cellular transformation. No common mutations were found among 190 known oncogenes (Data S5.) supporting the proposal 10 that random events accumulated to induce a transformed phenotype. Clustering analysis (Fig. 3A) (31) of the samples also indicates no clear relationship between conditions (Fig. 3B) . When using MutaGene (32) to investigate the specific type of nucleotide changes in the six foci compared to NIH/3T3 untreated cells, the mutational signature Cosmic 20 (Fig. 3C) , associated with defective mismatch repair and microsatellite instability, was observed across all samples. Interestingly, 15 when mismatch repair genes were analyzed in these foci samples, missense and nonsense mutations were found to be encoded by these transformed cells, indicating the genetic source for the mutation profile observed (Table 1) . Furthermore, none of the foci contain the same mutations.
Since all six foci where derived from treatment with a common promoter, it is tempting to propose that future studies might reveal that a promoter drives the selection for the mutator phenotype. 20 Herein we observe that exosomes from pancreatic cancer cell lines can initiate the transformation of normal cells (Fig. 3D) . Recently, analyses of neoplastic and carcinoma cells from pancreatic cancer patients demonstrated that adjacent cells from the same patient contain 9 unique driver mutations, supporting the proposal that the cells in a tumor can be derived from independent transformation events as opposed to exclusive clonal events (33). These studies in combination with the observations in this report support a unique view of cellular transformation and how it is driven by the dynamic conversation between normal and cancer cells. 
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References (34-39) Exosomes secreted by cancer cells are taken up by normal cells and have the capacity to act as an initiator by incorporating random changes into the recipient cell genome. These initiated cells, when exposed to a promoter, can be induced by further alterations to a transformed state that has the ability to grow into a 5 malignant tumor. 
